"OpportunityAnalyzer: Gaucher Disease - Opportunity Analysis and Forecast to 2024" Published

GlobalData estimated the 2014 sales for the Gaucher Disease (GD) market at approximately $875m across the 7MM (US, France, Germany, Italy, Spain, UK, and Israel). The US market contributed the majority of these sales, generating an estimated $482m. By the end of the forecast period in 2024, GD sales are expected to increase to $1.16 billion at a Compound Annual Growth Rate (CAGR) of 2.9%. The majority of these sales will continue to come from the US, which will represent approximately 56.2% of the GD market in the 7MM in 2024. GlobalData forecasts an increase in the number of diagnosed prevalent cases of GD, and therefore, an increase in the treated GD population. Improved diagnosis will be driven by increasing physician education and awareness of GD and its signs and symptoms. Despite the anticipated increase in the number of diagnosed prevalent cases of GD over the forecast period, it is expected that a large portion of the GD population will remain undiagnosed. This is due to continued late diagnosis and misdiagnosis of GD as a result of the heterogeneous manifestations of the disease. The sparsely populated GD pipeline, with no drugs in late-stage development, will further hinder the growth of the GD market.

Full Report Details at
- http://www.fastmr.com/prod/1124666_opportunityanalyzer_gaucher.aspx?afid=301

Key Questions Answered

* Although the use of enzyme replacement therapies (ERTs) and substrate reduction therapies (SRTs) has significantly changed the natural history of GD, with a marked decrease in morbidity, especially in Type 1 GD patients, GD market is still marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the GD market?
* The late-stage GD pipeline is very sparsely populated and there no drugs in late-stage development. Nevertheless, the GD market will experience substantial growth. What are the main drivers of this growth during 2014-2024? Which of the marketed drugs will have the highest peak sales at the highest CAGR, and why?

Key Findings

* GlobalData forecasts an increase in the number of diagnosed prevalent cases of GD, and therefore, an increase in the treated GD population. Improved diagnosis will be driven by increasing physician education and awareness of GD and its signs and symptoms. This is largely attributable to Genzyme's and Shire's continued efforts to raise awareness of rare diseases through organized events and established websites, and by sponsoring patient registries.
* Genzyme's recently approved oral substrate reduction therapy (SRT), Cerdelga (eliglustat), is more effective and safer than the other oral SRT, Zavesca (miglustat), and therefore will be used more commonly as an oral alternative to IV ERT in adult Type 1 GD patients. As Cerdelga is more expensive than the other GD therapies, it is expected to drive the growth of the GD market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024
- OpportunityAnalyzer: Axial Spondyloarthritis - Opportunity Analysis and Forecast to 2024 - Event-Driven Update
- OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecast to 2024
- OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024
- PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024